1
DIMARCHI RICHARD D: Amide based glucagon superfamily peptide prodrugs. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, June 24, 2010: WO/2010/071807 (45 worldwide citation)

Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the activ ...


2
Dimarchi Richard D: Glucagon/glp-1 receptor co-agonists. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, June 23, 2011: WO/2011/075393 (38 worldwide citation)

Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon recpeotr and the GLP-I receptor. In some embodiments, the glucago ...


3
DIMARCHI Richard D, ZHANG Lianshan: Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g, Glucagon superfamily peptides exhibiting g protein-coupled receptor activity. Indiana University Research And Technology Corporation, Marcadia Biotech, DIMARCHI Richard D, ZHANG Lianshan, BREEN John P, November 17, 2011: WO/2011/143208 (38 worldwide citation)

Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g. ...


4
Dimarchi Richard D: Dipeptide linked medicinal agents. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, July 15, 2010: WO/2010/080605 (37 worldwide citation)

A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipe ...


5
DIMARCHI Richard D, DIMARCHI Maria, CHABENNE Joseph: Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique, Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers. Indiana University Research And Technology Corporation, DIMARCHI Richard D, DIMARCHI Maria, CHABENNE Joseph, BREEN John P, December 29, 2011: WO/2011/163473 (36 worldwide citation)

Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon with (a) a substitution of Ser at position 16 of native glucagon (SEQ ID NO: 1) with an α,α-disubstituted amino acid, optionally alpha, aminoisobutyric acid; a substitution of the Gin at position ...


6
DIMARCHI Richard D, YANG Bin, FINAN Brian: Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire dhormone, Glucagon superfamily peptides exhibiting nuclear hormone receptor activity. Indiana University Research And Technology Corporation, DIMARCHI Richard D, YANG Bin, FINAN Brian, BREEN John P, November 17, 2011: WO/2011/143209 (35 worldwide citation)

Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a ...


7
DIMARCHI RICHARD D: Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, August 4, 2011: WO/2011/094337 (32 worldwide citation)

Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet ...


8
Lynch Kevin R, Macdonald Timothy L: Compounds active in spinigosine 1-phosphate signaling. University Of Virginia Patent Foundation, Lynch Kevin R, Macdonald Timothy L, BREEN John P, February 5, 2004: WO/2004/010949 (17 worldwide citation)

The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure of Formula (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl ...


9
DIMARCHI RICHARD D: Amide-based insulin prodrugs. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, July 15, 2010: WO/2010/080609 (12 worldwide citation)

Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and l ...


10
DIMARCHI RICHARD D: Insulin analogs. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, July 15, 2010: WO/2010/080606 (9 worldwide citation)

Full potency analogs of insulin are provided wherein the analog comprises a modification of the tyrosine residue at position 19 of the A chain.



Click the thumbnails below to visualize the patent trend.